STOCK TITAN

Plexus (PLXS) 10-K Filings

PLXS NASDAQ

Here are the 10-K annual reports from Plexus Corp (PLXS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow PLXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLXS filings page.

Rhea-AI Summary

Plexus Corp. (PLXS), which designs, manufactures and services complex products, reported fiscal 2026 net sales of $4,964.957 million, up from $4,032.966 million in fiscal 2025. Fiscal 2026 included 53 weeks, versus 52 weeks in 2025. Net income rose to $202.490 million from $172.885 million, and diluted earnings per share were $7.41 versus $6.26.

Operating cash flow fell to $61.8 million from $249.2 million; free cash flow fell to $(28.9) million from $154.0 million, and is a non-GAAP measure. Plexus repurchased common stock for $85.0 million in fiscal 2026. A program authorizing up to $100.0 million became effective after completion of the prior program, with the full authority remaining as of October 3, 2026. Fiscal 2027 capital expenditures are estimated at approximately $175.0 million. One Industrial customer represented approximately 11% of fiscal 2026 sales; Industrial accounted for 44% of sales, Healthcare/Life Sciences 39%, and Aerospace/Defense 17%.

Rhea-AI Summary

Plexus Corp. filed its Annual Report (10-K) for the fiscal year ended September 27, 2025. The company designs, manufactures and services highly complex products across Aerospace/Defense, Healthcare/Life Sciences, and Industrial markets, operating 26 facilities with a global team of over 20,000. Management targets long-term compounded annual revenue growth of 9–12% and a 15% ROIC; Plexus’ internal WACC for fiscal 2025 was 8.9%.

Customer exposure is diversified: approximately 190 customers in fiscal 2025 and no single customer over 10% of sales. Net sales mix in 2025 was 17% Aerospace/Defense, 40% Healthcare/Life Sciences, and 43% Industrial. Shares outstanding were 27,121,994 as of March 29, 2025; as of November 10, 2025, there were 26,774,415 shares outstanding. The company highlights robust certifications (including ISO and FDA-related capabilities) and details risk factors such as supply chain constraints, regulatory complexity, competition, and geopolitical volatility.